Physician profile
Bernard L Shipp
NPI 1457379398
$3,015.46
in general payments reported to CMS, 2019-2025
24 companies · $272 in 2025
The $272 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $354 · 2021: $625 · 2022: $538 · 2023: $538 · 2024: $470 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,279.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $478.45 | 2022-2025 | Acthar |
| Alcon Vision LLC | $473.11 | 2019-2025 | Clareon, Hydrus Microstent, Argos |
| Rxsight INC | $326.62 | 2022-2025 | Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Dompe US, INC. | $321.12 | 2021 | |
| Ivantis, INC | $197.54 | 2020-2021 | |
| Ocular Therapeutix, INC. | $193.66 | 2020-2025 | Dextenza |
| Johnson & Johnson Surgical Vision, INC. | $136.73 | 2019-2021 | |
| Eyepoint US, INC. | $125.58 | 2019-2020 | |
| Allergan, INC. | $125.50 | 2019-2021 | |
| Abbvie INC. | $123.75 | 2022-2025 | Xen Glaucoma Treatment System |
| Oyster Point Pharma, INC. | $74.14 | 2022-2025 | Tyrvaya, Ryzumvi |
| Amgen INC. | $63.44 | 2024-2025 | Tepezza |
| Sight Sciences, INC. | $63.02 | 2019-2024 | Omni Surgical System |
| Harrow Eye, LLC | $51.46 | 2023-2024 | Iheezo, Vevye |
| Horizon Therapeutics Plc | $43.82 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $41.06 | 2023-2025 | Xiidra, Miebo, Vyzulta |
| Rayner Intraocular Lenses Limited | $38.60 | 2022 | |
| Omeros Corporation | $28.05 | 2020-2021 | |
| Tarsus Pharmaceuticals, INC. | $25.26 | 2025 | Xdemvy |
| Iridex Corporation | $21.03 | 2022 | |
| New World Medical,INC. | $20.52 | 2023 | |
| Eyevance Pharmaceuticals LLC | $18.21 | 2022 | |
| Biotissue Holdings INC. | $13.23 | 2022 | |
| Sun Pharmaceutical Industries INC. | $11.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Shipp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.